Investing.com - Mainz Biomed BV reported on Wednesday second quarter earnings that matched analysts' forecasts and revenue that was inline with expectations.
Mainz Biomed BV announced earnings per share of $-0.46 on revenue of $150K. Analysts polled by Investing.com anticipated EPS of $-0.46 on revenue of $150K.
Mainz Biomed BV shares are down 13% from the beginning of the year and are trading at $8.69 , down-from-52-week-high.They are under-performing the S&P/TSX which is down 9.34% from the start of the year.
Mainz Biomed BV follows other major Healthcare sector earnings this month
Mainz Biomed BV's report follows an earnings beat by Medtronic on Tuesday, August 23, 2022, who reported EPS of $1.13 on revenue of $7.37B, compared to forecasts EPS of $1.12 on revenue of $7.22B.
Agilent Technologies had beat expectations on Tuesday, August 16, 2022 with third quarter EPS of $1.34 on revenue of $1.72B, compared to forecast for EPS of $1.2 on revenue of $1.64B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar